ECONOMY

Pfizer Raises Low-End Revenue Guidance Amid Strong Sales of Eliquis and Other Drugs

Pfizer surpasses earnings estimates and adjusts its COVID product revenue forecast downward.

4 August 2026 · 14:30 · 1 sources

Pfizer reported earnings that exceeded analyst estimates on August 4, 2026. The company raised the low end of its full-year revenue guidance, driven primarily by strong sales of the anticoagulant Eliquis and other medications. However, Pfizer lowered its revenue expectation for COVID-19 related products to $4 billion, down from approximately $5 billion previously. The updated guidance reflects ongoing changes in demand for Pfizer's COVID portfolio.

Sources

CNBC — Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

THE QUESTIONS THIS EVENT LEAVES BEHIND

Pfizer Raises Low-End Revenue Guidance Amid Strong Sales of Eliquis and Other Drugs

Sources

How might Pfizer's lowered COVID product revenue forecast affect its overall long-term strategy?

What factors contributed to the stronger-than-expected sales of Eliquis?

How will Pfizer balance investment between COVID products and other pharmaceuticals given shifting revenue expectations?

What risks does Pfizer face if the demand for COVID products continues to decline?

How could changes in regulatory or market conditions impact Pfizer's updated revenue projections?